Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a report released on Monday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Trading Down 5.9 %

NYSE NAVB opened at $0.11 on Monday. The stock has a market capitalization of $11.30 million, a price-to-earnings ratio of -0.39 and a beta of 1.54. Navidea Biopharmaceuticals has a twelve month low of $0.06 and a twelve month high of $0.35. The stock has a 50-day moving average of $0.09 and a 200 day moving average of $0.16.

Navidea Biopharmaceuticals (NYSE:NAVB) last posted its quarterly earnings results on Friday, August 11th. The company reported ($0.03) earnings per share (EPS) for the quarter.

Institutional Trading of Navidea Biopharmaceuticals

Hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC raised its stake in Navidea Biopharmaceuticals by 264.5% in the first quarter. Renaissance Technologies LLC now owns 238,133 shares of the company’s stock valued at $62,000 after buying an additional 172,800 shares in the last quarter. Allred Capital Management LLC increased its position in shares of Navidea Biopharmaceuticals by 78.4% during the second quarter. Allred Capital Management LLC now owns 293,838 shares of the company’s stock worth $27,000 after purchasing an additional 129,100 shares in the last quarter. Finally, State Street Corp increased its position in shares of Navidea Biopharmaceuticals by 1,631.1% during the second quarter. State Street Corp now owns 412,743 shares of the company’s stock worth $38,000 after purchasing an additional 388,900 shares in the last quarter. 15.75% of the stock is currently owned by institutional investors and hedge funds.

About Navidea Biopharmaceuticals

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.